
From: [REDACTED] (SANTE)
Sent: Wednesday 31 March 2021 15:09
To: [REDACTED] (SANTE)
Subject: BTO report: presentation of RRF (health system focus) to of AmCham EU's healthcare committee
Attachments: 2021-03-30 AmCham.pptx; 2021-03-30 AmCham.pptx

Dear [REDACTED]

Yesterday I joined the AmCham EU's healthcare committee (30 March 1.30)PM – 2.30PM) to present the Recovery and Resilience Facility.

The presentation was delivered following AmCham's request to the Commission.
Next to [REDACTED] (AmCham) the below industry representatives attended.

I presented the attached PPT

From the floor I received the following questions:

- The role of the RRF as regards long-term care and the digital transformation
 - I reiterated general eligibility criteria
 - I explained eHealth was explicitly referred to in the Commission's RRP guidance
 - I referred to various country reports across European Semesters that also touched upon coordination challenges between healthcare and long-term care
- The need for certain high-cost medicines to be considered as "investments" (for national accounting purposes)
 - I referred to parallel debates:
 - Pharmaceutical strategy and novel payment models
 - Eurostat and accounting rules
- The need to ensure long-term reform momentum, also in the macro-economic aftermath of COVID-19
 - I explained that one of the assessment criteria as explained in RRP guidance deals with the sustainability of investments
 - Overall, prior to COVID-19 health systems were showing promising signs of resiliently coping with demographic ageing(e.g. healthcare expenditures as a share of GDP stabilized)

(there was also a request to comment on the inception impact assessment/roadmap published yesterday on the review of the EU pharmaceutical acquis, which I declined)

First Name	Surname	Company	Function
		Gilead Sciences	
		MSD (Europe) Inc.	
		ABBVIE	
		Weber Shandwick	
		PFIZER	
		nterel	
		AMGEN	
		Cambre Associates	
		MSD (Europe) Inc.	
		BAXTER	
		GlaxoSmithKline	
		JOHNSON & JOHNSON	
		AMGEN	
		Amazon	
		BRISTOL-MYERS SQU	
		3M	
		Abbott	
		Eli Lilly	



European Commission

Directorate-General for Health and Food Safety
Unit B1 Performance of national health systems

B-1049 Brussels/Belgium

+

@ec.europa.eu